IL‑31 x IL‑4Rα
VIAL‑IL31xIL4Rα is a half‑life–extended bispecific antibody that targets IL‑31 and IL‑4Rα to concurrently block itch neuroinflammation and type‑2 inflammation, aiming for faster onset and more durable control in atopic dermatitis and related Type-2 inflammation conditions.
- First-in-class IL‑31 x IL‑4Rα bispecific to raise the efficacy bar in atopic dermatitis by blocking itch neuroinflammation and type‑2 inflammation together.
- Half‑life extension to enable sustained exposure and less frequent, maintenance‑friendly dosing.
Key Data
Based on in vitro and in vivo studies, VIAL-INHBE effectively demonstrates functional potency and target-binding comparable to or better than clinical programs.
Genetically validated target
- TMPRSS6 loss of function is genetically validated to improve iron homeostasis.
- Reduced TMPRSS6 activity raises hepcidin, improving iron balance and protecting against overload.
- Loss-of-function variants in the TMPRSS6 gene are associated with low hemoglobin and iron deficiency anemia.
Key data highlights
- VIAL-TMPRSS6 is progressing to demonstrate an equal-or-better profile across potency, dosing frequency, and safety compared to other assets in development for PV.
- VIAL-TMPRSS6 demonstrated superior stability in NHP liver lysates (S9 fractions) suggesting improved knockdown durability and the potential for less frequent dosing.
